Introduction {#Sec1}
============

*Pneumocystis jirovecii* pneumonia (PCP) is a major cause of acute respiratory failure and death in immunocompromised patients. Malignant disease with chemotherapy, corticosteroids treatment for inflammatory autoimmune diseases, and transplantation of solid organs or bone marrow are the leading causes of T cell suppression, which is associated with a high risk of opportunistic infections, including PCP \[[@CR1], [@CR2]\]. The mortality associated with PCP in the non-HIV population group remains high, ranging from 19 to 76% \[[@CR3]--[@CR5]\], despite the availability of effective antimicrobial agents such as trimethoprim/sulfamethoxazole (TMP-SMZ) and pentamidine.

Early studies done in HIV-positive patients showed that corticosteroids adjunctive treatment (CAT) was associated with a dramatic decrease in mortality during PCP episodes \[[@CR6], [@CR7]\]. The pathophysiology of PCP may differ between patients with and without HIV infection. Conceivably, these differences between the two populations might affect the ability of steroids therapy to provide therapeutic benefits \[[@CR8]\].

Alternative therapies such as the use of adjunctive agents in an effort to reduce the mortality associated with non-HIV population have been evaluated by several retrospective studies. Unfortunately, the data for CAT among the non-HIV population are highly controversial \[[@CR5], [@CR9]\], and one study even indicated potential harm with CAT in severe cases admitted into the intensive care unit (ICU) \[[@CR10]\].

Based on relatively limited and controversial data from studies available at this stage, the primary objective of this investigation was to systematically review the literature and perform a meta-analysis of available data relating to evaluation of whether CAT can reduce mortality in non-HIV patients with PCP.

Methods {#Sec2}
=======

Data source and study selection {#Sec3}
-------------------------------

A literature search of Pubmed, Medline, Embase, and Cochrane database from 1989 to September 2019 was performed to find published articles evaluating adjunctive corticosteroids therapy for patients with non-HIV PCP. We limited studies to human subjects and searched for the following terms: (Pneumocysti\*\[text word\] OR PCP\[text word\] OR "*Pneumocystis* Infections"\[MESH\] OR "*Pneumocystis jirovecii*"\[MESH\] OR "Pneumonia, *Pneumocystis*"\[MESH\] OR "*Pneumocystis* carinii"\[MESH\]) AND (treat\* \[text word\] OR adjunct\* \[text word\] OR treatment\* \[text word\] OR steroid\*\[text word\] OR corticosteroid\*\[text word\] OR glucocorticoid\*\[text word\] OR "Glucocorticoids"\[MESH\] OR "Adrenal Cortex Hormones"\[MESH\] OR "Steroids"\[MESH\]) NOT (("animals"\[MeSH\] NOT "humans"\[MeSH\]) AND ("non-HIV" OR "non-AIDS" OR "non-HIV-infected" OR "HIV-uninfected" OR "AIDS uninfected" OR "HIV-negative")). In addition, we also reviewed the references listed in the identified articles and performed a manual search of the related articles to identify all relevant and eligible articles and to minimize publication bias.

Two researchers screened and evaluated the eligibility of all studies independently, and a third reviewer intervened whenever there was a disagreement. The inclusion criteria were (1) original research report of PCP in non-HIV patients; (2) report of mortality from patients with non-HIV PCP; (3) reported with data on mortality between patients treated with and without adjunctive corticosteroids, and (4) written in English. The exclusion criteria were (1) written in languages other than English; (2) not related to PCP pneumonia; (3) not an original research; (4) in vitro studies; (5) reports of single case experiences. The intervention of interest was corticosteroids adjunctive therapy. The comparison groups were patients treated for non-HIV PCP with and without adjunctive corticosteroids. The outcome of interest was mortality in all non-HIV PCP patients and mortality in those with acute hypoxemic respiratory failure, as defined by the study investigators. The meta-analysis of observational studies in epidemiology criteria were used to conduct this investigation, and the article follows MOOSE criteria \[[@CR11]\].

Data extraction {#Sec4}
---------------

Two investigators extracted data independently from each eligible study, using a standardized data extraction form. Discrepancies in data extraction underwent arbitration by a third reviewer, and consensus was obtained by verbal discussion. Data collected from each study included author, year of study, country, age group of patients, number of patients, causes of immunosuppression, method of PCP diagnosis, treatment of PCP, definition of adjunctive corticosteroid use, dose of steroids used, and mortality.

Data synthesis and data analysis {#Sec5}
--------------------------------

Data on non-HIV PCP outcomes were collected from all articles. All-cause mortality and clinical cure rates, as defined by the individual studies, were the primary outcome measures used in this meta-analysis. Odds ratios for mortality were calculated for each article. The significance level for this meta-analysis model was set at *P* \< 0.05. Forest plots were provided for mortality in this meta-analysis. We used the Q statistic to test the existence of heterogeneity; a *P* value of less than 0.10 was considered significant for heterogeneity. *I*^2^ was employed to assess the proportion of total variability due to heterogeneity. An *I*^2^ value of approximately 25% was regarded as low heterogeneity, 50% as medium, and 75% as high heterogeneity. Publication bias was assessed and an applicability concerns graph/summary was conducted using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK).

For the mortality in all non-HIV PCP patients, we performed a subgroup meta-analysis on different types of mortality reported (ICU mortality, hospital mortality, 30-day mortality and 60-day mortality). For the mortality in patients with hypoxemia or respiratory failure, we performed a subgroup meta-analysis on different severity of hypoxemia: hypoxemia patients with a PaO~2~ \< 70 mmHg (including patients with 60 mmHg \< PaO~2~ \< 70 mmHg and patients with PaO~2~ \< 60 mmHg), and respiratory failure patients with a PaO~2~ \< 60 mmHg. For the different doses of CAT used, we performed a subgroup meta-analysis on different patients with high dose (\> 240 mg prednisone equivalent) or low dose (1 mg/kg/day prednisone equivalent) CAT.

Results {#Sec6}
=======

Literature search {#Sec7}
-----------------

The literature search yield a total of 259 articles possibly related to non-HIV PCP with CAT. By reviewing the titles and abstracts, studies were mainly excluded due to the following: not an original research (*n* = 46); reports of single case experiences (*n* = 35); only diagnostic studies (*n* = 33); only HIV patients (*n* = 24); written in languages other than English (*n* = 22); not related to PCP pneumonia(*n* = 15); not related to corticosteroids therapy (*n* = 13); in vivo/in vitro studies (*n* = 5). After the initial screening, 66 articles with data on treatment of non-HIV PCP remained for full-text review. Of these, 50 articles were excluded from further analysis because they did not include outcome data (*n* = 43), reports of PCP colonization without evidence of infection (*n* = 5), or duplicated reports (*n* = 2). In the final analysis, 16 retrospective cohort investigations of patients treated with CAT were included \[[@CR3]--[@CR5], [@CR9], [@CR12]--[@CR23]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of study selection, process and reasons for exclusion of references

Study characteristics {#Sec8}
---------------------

Demographic variables of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. A total of 16 studies involving 2518 patients were included in this meta-analysis. The 16 studies were conducted in 7 countries as France (*n* = 4), Japan (*n* = 4), United States (*n* = 2), China (*n* = 2), Korea (*n* = 2), Italy (*n* = 1), and Greece (*n* = 1).Table 1Studies characteristics included in this meta-analysisSeries no.References author, year of publishStudy designCountryTotal no. of patientsCauses of immunosuppressionMethod of PCP diagnosisDefinition of adjunctive corticosteroids use1Pareja, 1998Retrospective single centerUSA30Organ transplantation = 13; longterm immunosuppressive therapy = 9;Chemotherapy for malignancy = 8Morphological≥ 60 mg prednisone daily equivalent2Delclaux, 1999Retrospective two centerFrance31Hematologic malignancy = 24; vasculitis = 3; solid tumor = 2; other = 2Morphological (demonstration of typical organism in specimens BALF)1. De novo therapy (for patients who did not receive previous CS): oral prednisone \> 1 mg/kg/day or iv methylprednisolone 240 mg for 3 days- \> 120 mg for 3 days- \> 60 mg for 3 days or longer2. Rescue therapy(for patients already receiving CS): corticosteroid increased at least 300% of the baseline3Zahar, 2002Retrospective two centerFrance39Malignancy: hematological malignancies = 28Solid tumor = 7; nonmalignant hematological diseases = 4Positive results for cytological tests or direct fluorescent antibody staining for PCP in sputum or BALF240 mg/day for 3 days, with the dosage then tapered during the next 10 days, until no therapy was given4Pagano, 2002Retrospective multicenterItaly55Malignant hematological diseases: on-Hodgkin's lymphoma = 18Acute lymphoblastic leukemia = 10Acute myeloid leukemia = 8; chronic myeloid leukemia = 5Microbiologically (positive visualization, mAbs, or PCR of PC in sputum or BALF) and/or histologically documentedMethylprednisolone (50--80 mg/day)5Roblot, 2003Retrospective multicenterFrance60Hematologic malignancies: non-Hodgkin's malignant lymphoma = 18Chronic lymphocytic leukemia = 13; acute leukemia = 10Multiple myeloma = 5; Waldenstro¨m's diseases = 4; chronic myeloid leukemia = 4Myelodysplasia = 3; Hodgkin's diseases = 2; thrombopenia = 1Microbiological evidence of PC in BALF (silver and eosin þ methylene blue stainings and/or immunostaining using monoclonal antibodies)Dose and duration of adjunctive corticosteroids use was not detailed reported6Bollee, 2007Retrospective single centerFrance56Cancer: hematologic malignancies = 44; solid tumors = 12PCP with Giemsa staining and/or immunofluorescence with human monoclonal anti-Pneumocystis cyst antibodies in BALF or sputum1 mg/kg of prednisone (or equivalent) per day or in a 30-mg increase in the daily prednisone dosage7Aoki, 2009Retrospective single centerJapan25Collagen vascular diseasesElevated concentration of plasma 1,3-[d]{.smallcaps}-glucan, and positive PCR test for PCP in sputumDose and duration of adjunctive corticosteroids use was not detailed reported8Matsumura, 2011Retrospective multicenterJapan82Inflammatory diseases = 50; solid malignancies = 17Hematological malignancies = 12; transplantations = 6Diagnosed with PCP by PCRDose and duration of adjunctive corticosteroids use was not detailed reported9Moon, 2011Retrospective single centerKorea88Solid-organ transplant = 26; hematologic malignancy = 26Non-hematologic malignancy = 12; interstitial lung disease = 9Connective tissue disease = 7; others = 8Diagnosis was based on a positive result in the direct immunofluorescence assay for PCPAt least 40 mg prednisone twice daily for 5 days10Kim, 2014Retrospective multicenterKorea173Hematologic malignancy = 81; solid tumors = 38Organ transplantations = 17; others = 37Positive direct fluorescent antibody (DFA) or PCR results from a sputum or BAL fluid sampleDose and duration of adjunctive corticosteroids use was not detailed reported11Kofteridis, 2014Retrospective single centerGreece62Malignant hematological disease = 31; solid tumor = 16Chronic inflammatory disease = 15Positive results of direct fluorescent antibody staining for PCP in samples of induced sputum or BALFDose and duration of adjunctive corticosteroids use was not detailed reported12Weng, 2016Retrospective multicenterChina82CTD = 65; organ transplant = 3; hematologic malignancy = 3;solid tumor = 4PCR or methenamine silver stain of samples from BALF, aspirate or sputumDose and duration of adjunctive corticosteroids use was not detailed reported13Kotani, 2017retrospectivesingle centerJapan20Rheumatoid arthritis or CTD = 9; renal transplant = 7; other = 4By fluorescent antibody staining using induced sputum or BALFMethylprednisolone was dependent on the prior dosage of steroids and any underlying diseases14Wieruszewski, 2018Retrospective single centerUSA332Hematologic malignancy = 162; bone marrow transplantation = 26Inflammatory of connective tissue disease = 100Solid organ tumor = 61; solid organ transplantation = 20A Positive single-copy PCP PCR or smear from a respiratory specimenCorticosteroids within 48 h15Inoue, 2019Retrospective multicenterJapan1299After transplantation = 34; solid tumor = 245Malignancy of lymphoid tissue = 160; rheumatoid arthritis = 257Connective tissue disease = 80Based on recordsAdjunctive corticosteroids were defined \< 250 mg/day corticosteroids or high dose pulse steroid therapy which refers to the administration of 250 mg prednisone equivalent a day for one or a few days (usually less than 5 days)16Liu, 2019Retrospective single centerChina84Hematologic malignancy = 29; autoimmune diseases = 21Solid cancers = 17; solid organ transplantation = 7Quantitative real-time PCRAdjunctive steroids were high dose (≥ 1 mg/kg/day)BALF, bronchoalveolar lavage fluid; PC, Pneumocystis; PCP, *Pneumocystis* pneumonia; *DFA* direct fluorescent antibody; *PCR* polymerase chain reaction

The type of immunocompromised diseases of non-HIV patient population included hematological malignancies (*n* = 715), solid tumor (*n* = 421), rheumatoid arthritis (*n* = 257), solid organ transplantation (n = 133), and other inflammatory autoimmune diseases (*n* = 393, including collagen vascular disease, interstitial lung disease, connective tissue disease) (Table [1](#Tab1){ref-type="table"}).

Diagnosis of PCP was based on methenamine silver stain under microscopic examination (7 studies), fluorescent antibody staining (8 studies), or polymerase chain reaction (4 studies) of the patients' sputum/bronchoalveolar lavage fluid, or transbronchial biopsy (1 study), or elevated concentration of plasma 1,3-[d]{.smallcaps}-glucan (1 study) (Table [1](#Tab1){ref-type="table"}).

The included investigations differed in their definition of CAT from different centers (shown in Table [1](#Tab1){ref-type="table"}). The investigations defined CAT use as prednisone doses greater than 60 mg/day or methylprednisolone 50--80 mg/day, pulse corticosteroids(high dose corticosteroids as 240 mg/day for 3 days, with the dosage then tapered during the next 10 days, until no therapy was given), prednisone doses of 80 mg or greater, and prednisone doses \> 1 mg/kg.

Studies also differed in their definition of mortality (Table [2](#Tab2){ref-type="table"}). Six investigations used in-hospital mortality rates, six investigations used 30 day all-cause mortality, two used 60 day all-cause mortality, and two used ICU mortality rates.Table 2Studies included in this meta-analysis of the impact of adjunctive corticosteroids on mortality of non-HIV PCPSeries no.References author, year of publishStudy designCountryHospital or centersStudy periodTotal no. of patientsMajor outcome reportedMortalityNo CAT mortalityCAT mortalityCases of hypoxemic respiratory dysfunction (hypoxemia: PaO~2~ \< 70 mmHg on room air; respiratory failure: PaO~2~ ≤ 60 mmHg on room air)Mortality in respiratory failure PCPMortality in hypoxic PCP and no CATMortality in hypoxic PCP and with CAT1Pareja, 1998Retrospective single centerUSA1 tertiary care urban teaching hospital1989--199530In-hospital mortality12/30 (40%)5/14 (36%)7/16 (44%)21/30 (70%, hypoxemia)12/21 (57.1%)4/9 (44.4%)8/12 (66.7%)2Delclaux, 1999Retrospective two centerFrance2 medical ICUs1988--199631ICU mortality13/31 (42%)4/8 (50%)9/23 (39%)31/31 (100%, respiratory failure)13/31 (42%)4/8 (50%)9/23 (39%)3Zahar, 2002Retrospective two centerFrance2 medical ICUs1989--19993930-day mortality13/39 (33%)3/8 (38%)10/31 (32%)39/39 (100%, respiratory failure)13/3 (33%)3/8 (38%)10/31 (32%)4Pagano, 2002Retrospective multicenterItaly52 hematology divisions1990--19995530-day mortality20/55 (36%)12/33 (36%)8/22 (36%)39/55 (71%, hypoxemia)N/AN/AN/A5Roblot, 2003Retrospective multicenterFrance11 infectious diseases units1995--19996030-day mortality20/60 (33%)5/25 (20%)15/35 (43%)N/AN/AN/AN/A6Bollee, 2007Retrospective single centerFrance1 adult cancer center2001--200656In-hospital mortality11/56 (20%)9/35 (26%)2/21 (10%)56/56 (100%, hypoxemia)11/56 (20%)9/35 (26%)2/21 (10%)7Aoki, 2009Retrospective single centerJapan1 university hospital2000--200725In-hospital mortality11/25 (44%)4/12 (33%)7/13 (54%)25/25 (100%, hypoxemia)11/25 (44%)4/12 (33%)7/13 (54%)8Matsumura, 2011Retrospective multicenterJapan2 university hospital2005--20108230-day mortality20/82 (24%)4/22 (18%)16/60 (27%)57/82 (70%, hypoxemia)18/57 (32%)N/AN/A9Moon, 2011Retrospective single centerKorea1 university hospital2007--20108830-day mortality28/88 (32%)10/29 (35%)18/59 (31%)54/88 (61%, respiratory failure)28/54 (52%)10/17 (59%)18/37 (49%)10Kim, 2014Retrospective multicenterKorea2 tertiary care university hospitals2004--2011173In-hospital mortality62/173 (36%)0/21 (0%)62/152 (41%)88/173 (51%, respiratory failure)N/AN/AN/A11Kofteridis, 2014Retrospective single centerGreece1 university hospital2004--201362In-hospital mortality18/62 (29%)3/12 (25%)15/50 (30%)12/62 (19%, hypoxemia)N/AN/AN/A12Weng, 2016Retrospective multicenterChina4 ICUs from 2 centers2012--201582ICU mortality62/82 (76%)14/18 (78%)48/64 (75%)82/82 (100%, respiratory failure)62/82 (76%)14/18 (78%)48/64 (75%)13Kotani, 2017Retrospective single centerJapan1 ICU2008--201220In-hospital mortality4/20 (20%)1/11 (9%)3/9 (33%)N/AN/AN/AN/A14Wieruszewski, 2018Retrospective single centerUSA1 teaching hospital2006--201633230-day mortality74/332 (23%)6/74 (9%)68/258 (26%)N/AN/AN/AN/A15Inoue, 2019Retrospective multicenterJapanNationwide records study2010--2016129960-day mortality247/1299 (19%)34/159 (21%)213/1140 (19%)737/1299 (57%, respiratory failure)189/737 (26%)26/71 (37%)163/661 (25%)16Liu, 2019Retrospective single centerChina1 medical center2015--20168460-day mortality39/84 (46%)16/41 (39%)23/43 (53%)57/84 (68%, respiratory failure)N/AN/AN/ATotal1998 \~ 201916 retrospective 8 single center 8 multi centerFrom 7 countries1 nationwide data8 hospital wide data4 ICU wide data3 ward wide data1989--201625182 for ICU mortality6 for in-hospital mortality6 for 30-day mortality2 for 60-day mortality654/2518 (26%)130/522 (25%)524/1996 (26%)6 with hypoxemia (3 with CAT use reported)7 with respiratory failure (5 with CAT use reported)339/1040 (33%)74/178 (42%)265/862 (31%)CAT, corticosteroids adjunctive therapy; ICU, intensive care unit; N/A, not available; PCP, *Pneumocystis* pneumonia

Impact of corticosteroids adjunctive therapy on mortality of non-HIV PCP {#Sec9}
------------------------------------------------------------------------

We performed a meta-analysis on mortality associated with or without CAT in 16 studies in all non-HIV PCP patients (Table [2](#Tab2){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} shows treatment with CAT for non-HIV PCP patients have an significant impact on mortality (odds ratio, 1.37; 95% confidence interval 1.07--1.75; *P* = 0.01). The CAT was related with a higher mortality in all non-HIV PCP patients included.Fig. 2Forest plot for effect of corticosteroids adjunctive therapy (CAT) on mortality of non-HIV PCP

Subgroup analysis for different types of mortality were performed (as shown in Additional file [1](#MOESM1){ref-type="media"}: Figure 2.2). Treatment with CAT for non-HIV PCP patients had no significant impact on ICU mortality (odds ratio, 0.77; 95% confidence interval 0.29--2.08; *P* = 0.61, Additional file [1](#MOESM1){ref-type="media"}: Figure 2.2.1) and 60-day mortality (odds ratio, 0.97; 95% confidence interval 0.67--1.41; *P* = 0.89, Additional file [1](#MOESM1){ref-type="media"}: Figure 2.2.4). Treatment with CAT for non-HIV PCP patients had a significant impact on hospital mortality (odds ratio, 2.14; 95% confidence interval 1.17--2.91; *P* = 0.01, Additional file [1](#MOESM1){ref-type="media"}: Figure 2.2.2) and 30-day mortality (odds ratio, 1.85; 95% confidence interval 1.20--2.84; *P* = 0.005, Additional file [1](#MOESM1){ref-type="media"}: Figure 2.2.3).

Impact of corticosteroids adjunctive therapy on mortality of non-HIV PCP with hypoxemia or respiratory failure {#Sec10}
--------------------------------------------------------------------------------------------------------------

We performed another meta-analysis on mortality associated with or without CAT in 8 studies in which non-HIV PCP patients with hypoxemia or acute hypoxemic respiratory failure were reported (Table [2](#Tab2){ref-type="table"}). Figure [3](#Fig3){ref-type="fig"} shows CAT was related to a trend of lower mortality for non-HIV PCP patients with hypoxemia (odds ratio, 0.69; 95% confidence interval 0.47--1.01; *P* = 0.05).Fig. 3Forest plot for effect of corticosteroids adjunctive therapy (CAT) on mortality of non-HIV PCP with acute hypoxemic respiratory failure

Subgroup analysis for hypoxemia or respiratory failure was performed (as shown in Fig. [4](#Fig4){ref-type="fig"}). Treatment with CAT for non-HIV PCP patients with hypoxemia had no significant impact on mortality (odds ratio, 1.06; 95% confidence interval 0.44--2.57; *P* = 0.89, Fig. [4](#Fig4){ref-type="fig"}a). Treatment with CAT for non-HIV PCP patients with respiratory failure had a significant impact on mortality (odds ratio, 0.63; 95% confidence interval 0.41--0.95; *P* = 0.03, Fig. [4](#Fig4){ref-type="fig"}b). CAT was related to a significantly lower mortality for non-HIV PCP patients with respiratory failure.Fig. 4Forest plot of subgroup analysis for effect of corticosteroids adjunctive therapy (CAT) on mortality of non-HIV PCP with hypoxemia or respiratory failure

Impact of high- or low-dose corticosteroids adjunctive therapy on mortality of non-HIV PCP {#Sec11}
------------------------------------------------------------------------------------------

High dose (\> 240 mg prednisone equivalent) or low dose (1 mg/kg/day prednisone equivalent) CAT were reported in 7 studies in non-HIV PCP patients. We performed another meta-analysis on mortality associated with or without CAT in different CAT doses. Figure [5](#Fig5){ref-type="fig"} shows CAT dose had no relation with a lower mortality for non-HIV PCP patients (odds ratio, 0.92; 95% confidence interval 0.68--1.25; *P* = 0.59).Fig. 5Forest plot for effect of different doses of corticosteroids adjunctive therapy (CAT) on mortality of all non-HIV PCP patients

Subgroup analysis for hypoxemia patients with high or low dose CAT were performed (as shown in Fig. [6](#Fig6){ref-type="fig"}). Treatment with low dose CAT for non-HIV PCP patients with hypoxemia had a significant impact on mortality (odds ratio, 0.61; 95% confidence interval, 0.39--0.94; *P* = 0.02, Fig. [6](#Fig6){ref-type="fig"}a). Treatment with high dose CAT for non-HIV PCP patients with hypoxemia had no significant impact on mortality (odds ratio, 0.79; 95% confidence interval 0.16--4.00; *P* = 0.78, Fig. [6](#Fig6){ref-type="fig"}b). Low dose CAT was related to a significantly lower mortality for non-HIV PCP patients with hypoxemia.Fig. 6Forest plot of subgroup analysis for effect of different doses of corticosteroids adjunctive therapy (CAT) on mortality of non-HIV PCP with hypoxemia or respiratory failure

Subgroup analysis of studies published before or after 2005 {#Sec12}
-----------------------------------------------------------

Based on over 20 years of publication range (from 1998 to 2019) of included studies, all studies published after 2005 had an inclusion period after 2000, which may represent different ventilation strategies (lung protective ventilation for ARDS) applied to severe PCP pneumonia induced respiratory failure. Subgroup analysis for the impact of publication range on studies was performed.

In subgroup analysis of 11 studies published after 2005, treatment with CAT for non-HIV PCP patients had a significant impact on mortality (odds ratio, 1.39; 95% confidence interval 1.07--1.75; *P* = 0.01, Fig. [7](#Fig7){ref-type="fig"}b). In subgroup analysis of five studies with hypoxemia or respiratory failure published after 2005, Fig. [8](#Fig8){ref-type="fig"}b shows CAT was related to a significantly lower mortality for non-HIV PCP patients with hypoxemia (odds ratio, 0.64; 95% confidence interval 0.42--0.96; *P* = 0.03).Fig. 7Forest plot of subgroup analysis of studies published before and after 2005 for effect of different doses of corticosteroids adjunctive therapy (CAT) on mortality of all non-HIV PCP patientsFig. 8Forest plot of subgroup analysis of studies before and after 2005 for effect of different doses of corticosteroids adjunctive therapy (CAT) on mortality of non-HIV PCP patients with hypoxemia or respiratory failure

Publication bias {#Sec13}
----------------

More than eight studies reported mortality in all studies and in studies with hypoxemia patients, so we used funnel plot analysis to assess publication bias. As shown in Additional file [2](#MOESM2){ref-type="media"}, there was no obvious evidence of publication bias for mortality in all studies and in studies with hypoxemia patients by funnel plots.

Discussion {#Sec14}
==========

Our systematic review and meta-analysis revealed for the first time that CAT is harmful in unselected non-HIV PCP patients with or without respiratory failure, but may reduce mortality in the subgroup of non-HIV PCP patients who have acute hypoxemic respiratory failure. The main strength of our study is that it had the largest sample size of 2518 cases from 16 studies of non-HIV PCP patients treated with or without CAT.

Firstly, our analysis found that when evaluated in the whole non-HIV PCP population, CAT showed an association with higher mortality. This result indicated that CAT may increase the mortality in unselected PCP patients, including those with or without hypoxemia. This finding is different from that in the HIV-infected population. In a large RCT for HIV-PCP \[[@CR7]\], clinical benefit of early CAT could not be demonstrated for HIV-infected patients with mild hypoxemia (a partial pressure of oxygen greater than 75 mmHg on room air), but CAT also showed no harm for mortality. In the most recent two large sample studies in non-HIV PCP, there was no difference in mortality between CAT and no CAT \[[@CR4], [@CR5]\].

Secondly, our analysis found a probable association between CAT and low mortality in non-HIV PCP patients with hypoxemia or respiratory failure (OR = 0.69, 95% CI 0.47--1.01, *P* = 0.05). This result is similar to findings from the HIV-infected patients. Prospective studies in hypoxemic HIV patients with PCP found that early initiation of corticosteroids reduced the need for mechanical ventilation and conferred the greatest mortality benefit \[[@CR6], [@CR7], [@CR24], [@CR25]\]. Moon et al. \[[@CR19]\] evaluated CAT in moderate to severe non-HIV PCP, and also indicated that CAT may not improve the outcome of PCP in non-HIV patients. However, when considering the heterogeneity of the present analysis (*I*^2^ = 47%), the different treatment protocols between studies and the long time elapsed between the different studies can lead to wide differences in the prognosis of critically ill patients, including mechanically ventilated patients. Furthermore, as for the *P* = 0.05, this result could not be considered for a conclusive negative recommendation of CAT use in non-HIV PCP with respiratory insufficiency. The negative result may be due to the design of this analysis, which only included retrospective observational studies, and used different definitions in time and dose of CAT use, which led to heterogenous effects to the outcome.

Thirdly, our analysis found an association between CAT and low mortality in non-HIV PCP patients with respiratory failure(PaO~2~ \< 60 mmHg). Limited studies reported the effects of CAT on mortality of non-HIV PCP with respiratory failure. Pareja et al. \[[@CR9]\] described that the adjunctive corticosteroids shortened the duration of the mechanical ventilation and may accelerate recovery in cases of non-HIV PCP. Although their study suggested potential benefit of using CAT, it showed no difference in mortality. Lemiale et al. \[[@CR10]\] focused on the effect of CAT in non-HIV severe PCP admitted to ICU, and found that high dose steroid was even associated with increased mortality. And recently, Inoue et al. \[[@CR4]\] analyzed the severe non-HIV PCP group with and without CAT in a nationwide case series, and revealed that CAT was associated with lower risk of 60-day mortality in non-HIV PCP patients with severe respiratory failure. Moreover, even though a low PaO~2~ (\< 60 mmHg) is part of the definition of acute respiratory insufficiency, the use of the level of PaO~2~ alone has some limits to adequately report the severity of *Pneumocystis* pneumonia. The use of PaO~2~/FiO~2~ may be more informative to this purpose. This may have a great impact on the results of the present analysis. The future analysis should consider PaO~2~/FiO~2~ rather than PaO~2~ alone to classify the patients. However, because there were fewer number of studies included, and the standard of the hypoxemia or respiratory failure was subjective based on the retrospective observational studies, the results from the subgroup analysis on hypoxemia and respiratory failure was inconclusive at this stage. Although not definitive, this subgroup analysis at least suggested that CAT may have the potential benefit for mortality in patients with hypoxemia and respiratory failure.

Finally, when we combined the results that CAT increased mortality in unselected non-HIV PCP patients, there was a trend of decreasing mortality in moderate and severe PCP patients with hypoxemia, and significantly decreased mortality in patients with respiratory failure, indicating that CAT may be associated with an increased mortality mainly in PCP without hypoxemia, and with a decreased mortality mainly in severe non-HIV PCP with respiratory failure. These findings is different from that in the HIV-PCP \[[@CR4], [@CR5], [@CR7]\]. Therefore, based on our analysis, we speculated that CAT may be avoided in non-HIV PCP without hypoxemia, and may be considered in those with respiratory failure.

Moreover, comparing the impact of high and low doses of corticosteroids is of critical importance. Indeed, corticosteroids are in some patients the factor leading to the development of PCP, and low doses may only represent (both in the physician point of view and by its proper effect) the continuation of the treatment instead of an adjunctive therapy. The classification proposed by Lemiale et al. \[[@CR10]\] was very meaningful in terms of the dosage of corticosteroids: no corticosteroids, low dose or high dose. In the study by Inoue and coworkers, patients with respiratory failure had received low dose corticosteroids (mean dose of equivalent prednisone in the present study was 39 mg/day), and they found benefits on mortality with low dose (17--36 mg/day) by subgroup of corticosteroids daily dose, a result quite similar to that proposed in Lemiale's study.

Our analysis has limitations. First, all studies included were retrospective studies, no prospective randomized trials were included. The studies included used different definitions in CAT and type of mortality, which led to heterogenous effects on the outcome. Moreover, this meta-analysis was performed on retrospective studies, and timing and dose of steroid in severe patients were not clearly described. However, we did subgroup analysis to explore potential heterogeneity. Second, due to lack of reported data, alternative endpoints other than mortality, such as intubation rate, duration of ventilation, and length of hospital/ICU stay, were unable to be analyzed.

Conclusions {#Sec15}
===========

This systematic review and meta-analysis included 16 studies with 2518 participants, providing an overview of research on CAT for non-HIV PCP. Our meta-analysis suggests that among non-HIV PCP patients with respiratory failure, CAT use may be associated with better clinical outcomes, and it may be associated with increased mortality in unselected non-HIV PCP population. We believe that clinical trials are needed to compare CAT vs no-CAT in non-HIV PCP patients with respiratory failure. Furthermore, CAT use may be withheld in non-HIV PCP patients without hypoxemia.

Supplementary information
=========================

 {#Sec16}

**Additional file 1: Figure 2.2.** Subgroup analysis for diferent types of mortality. **Additional file 2.** Result of publication bias.

ICU

:   Intensive care unit

RF

:   Respiratory failure

CAT

:   Corticosteroids adjunctive therapy

PCP

:   *Pneumocystis jirovecii* pneumonia
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